Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
MAVORIC Investigators
Dermatology
Research output
:
Contribution to journal
›
Article
›
peer-review
395
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
mogamulizumab
100%
Vorinostat
76%
Cutaneous T-Cell Lymphoma
70%
Mycosis Fungoides
12%
Research Personnel
8%
Progression-Free Survival
8%
Cellulitis
7%
Pulmonary Embolism
6%
Intention
5%
Japan
5%
Therapeutics
5%
Sepsis
5%
Polymyositis
4%
Bronchopneumonia
4%
CC Chemokines
4%
Population
3%
Safety
3%
Chemokine Receptors
3%
Switzerland
3%
Denmark
3%
Spain
3%
Netherlands
3%
Italy
3%
Non-Hodgkin's Lymphoma
3%
France
2%
Germany
2%
Fever
2%
Monoclonal Antibodies
2%
Randomized Controlled Trials
2%
Morbidity
1%
Kidney
1%
Liver
1%
Mortality
1%
Pharmaceutical Preparations
1%